Exemestan in breast cancer treatment
Journal Title: OncoReview - Year 2012, Vol 2, Issue 4
Abstract
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials results indicates aromatase inhibitors as a valuable alternative for postmenopausal patients. Exemestane is a steroid aromatase inhibitor with effectiveness proven in clinical trials discussed in this article.
Authors and Affiliations
Elżbieta Wójcik
Keywords
Related Articles
- EP ID EP53184
- DOI -
- Views 240
- Downloads 0
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
Meeting the human
We often have to deal with problems which force us to making difficult choices and decisions that have not only clinical aspects but also ethical during the oncologist’s work. Unfortunately there is not enough place in a...
Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth hormone 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adeno...
Dermatofibrosarcoma protuberans (DFSP) – postępy w diagnostyce i leczeniu
Dermatofibrosarcoma protuberans jest rzadkim, rosnącym powierzchownie, mięsakiem tkanek miękkich występującym z częstością ok. 4 przypadków na milion osób rocznie. Zwykle rozwija się na skórze tułowia, występuje we wszys...
Stanowisko w sprawie stosowania niepegylowanej liposomalnej doksorubicyjny u chorych na chłonniaki ze współistniejącymi chorobami sercowo-naczyniowymi